Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
GlaxoSmithKline
All patients will receive weekly topotecan.
Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break. Cycles are repeated every 8 weeks, for 3 cycles. Restaging studies will be performed every cycle (or 8 weeks.)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Extensive small cell lung cancer with progression after one previous chemotherapy or chemotherapy/radiation therapy regimen
Measurable or evaluable disease
Able to perform activities of daily living with minimal assistance
Adequate bone marrow, liver and kidney function
May have received no more than 3 previous courses of radiation therapy
Give written informed consent prior to study entry
You may not be if
Patients with limited stage disease
History of a prior malignancy within three years
Female patients who are pregnant or are breast feeding
Significant history of uncontrolled cardiac disease
Myocardial infarction or stroke within six months
Symptomatic peripheral vascular disease
CNS involvement
Serious active infection or underlying medical condition
